PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease-Reference-Cited by-同舟云学术

PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease

Published:2017-04-28 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Schmidt Amand F¹,Pearce Lucy S²,Wilkins John T³,Overington John P⁴,Hingorani Aroon D¹,Casas Juan P⁵

Affiliation:

1. University College London; Institute of Cardiovascular Science; 222 Euston Road, Room 206 London UK NW1 2DA

2. London School of Hygiene & Tropical Medicine; Department of Non-communicable Disease Epidemiology; Keppel Street London UK WC1 E7HT

3. Northwestern University Feinberg School of Medicine; The Department of Medicine (Cardiology) and the Department of Preventive Medicine; Suite 1400 680 N. Lakeshore Drive Chicago Illinois USA 60611

4. Medicines Discovery Catapult; 40 Churchway Alderly Edge UK SK10 4TG

5. University College London; Farr Institute of Health Informatics Research; 222 Euston Road London UK NW1 2DA

Publisher

Wiley

Subject

Pharmacology (medical)

Link

https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011748.pub2/epdf/full

Reference111 articles.

1. Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia;Ballantyne;American Journal of Cardiology,2015

2. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia;Blom;New England Journal of Medicine,2014

3. Tingley W Mosesova S Baruch A Davis JD Budha N Vilimovskij A Effects of RG7652, a monoclonal antibody against proprotein convertase Subtilisin/Kexin type 9, on LDL cholesterol in patients with coronary heart disease or high risk: results from the EQUATOR study European Heart Journal 2014 371

4. Evolocumab and clinical outcomes in patients with cardiovascular disease;Sabatine;New England Journal of Medicine,2017

5. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial;Moriarty;Journal of Clinical Lipidology,2015

Cited by 118 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Safety of Alirocumab and Evolocumab as Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors in Familial Hypercholesterolemia: A Systematic Review and Meta-Analysis;Current Medicinal Chemistry;2024-01

2. Obesity and Dyslipidemia;Current Atherosclerosis Reports;2023-11-18

3. GWAS of lipids in Greenlanders finds association signals shared with Europeans and reveals an independent PCSK9 association signal;European Journal of Human Genetics;2023-10-30

4. Integrating metabolomics and proteomics to identify novel drug targets for heart failure and atrial fibrillation;2023-10-19

5. PCSK-9 Inhibitors and Cardiovascular Outcomes: A Systematic Review With Meta-Analysis;Cureus;2023-10-06